Gilberto de Castro Junior
Gilberto de Castro Junior
Médico Assistente Doutor, Serviço de Oncologia Clínica, Instituto do Câncer do Estado de São Paulo
Dirección de correo verificada de lim24.fm.usp.br
TítuloCitado porAño
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ...
The Lancet 387 (10027), 1540-1550, 2016
29752016
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E De Azambuja, F Cardoso, G de Castro, M Colozza, MS Mano, ...
British journal of cancer 96 (10), 1504-1513, 2007
8782007
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
4672017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
D Cameron, MJ Piccart-Gebhart, RD Gelber, M Procter, A Goldhirsch, ...
The Lancet 389 (10075), 1195-1205, 2017
2902017
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum …
JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ...
The Lancet Oncology 16 (5), 583-594, 2015
286*2015
side effects of approved molecular targeted therapies in solid cancers.
C Widakowich, E De Azambuja, P Dinh, A Awada
Oncologist 12 (12), 2007
2852007
Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation
P Lothaire, E de Azambuja, D Dequanter, Y Lalami, C Sotiriou, G Andry, ...
Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2006
1912006
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ...
The Lancet 393 (10167), 156-167, 2019
1652019
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥ 1%: open-label …
G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, ...
Journal of Clinical Oncology 36 (18_suppl), LBA4-LBA4, 2018
1522018
Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
K Cocks, MT King, G Velikova, G de Castro Jr, MM St-James, PM Fayers, ...
European journal of cancer 48 (11), 1713-1721, 2012
1492012
Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm)
G de Castro Junior, F Puglisi, E de Azambuja, NS El Saghir, A Awada
Critical reviews in oncology/hematology 59 (1), 40-50, 2006
1092006
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised …
L Paz-Ares, J Mezger, TE Ciuleanu, JR Fischer, J von Pawel, M Provencio, ...
The Lancet Oncology 16 (3), 328-337, 2015
1082015
Regenerative potential of leucocyte‐and platelet‐rich fibrin. Part B: sinus floor elevation, alveolar ridge preservation and implant therapy. A systematic review
AB Castro, N Meschi, A Temmerman, N Pinto, P Lambrechts, W Teughels, ...
Journal of clinical periodontology 44 (2), 225-234, 2017
882017
Regenerative potential of leucocyte‐and platelet‐rich fibrin. Part A: intra‐bony defects, furcation defects and periodontal plastic surgery. A systematic review and meta‐analysis
AB Castro, N Meschi, A Temmerman, N Pinto, P Lambrechts, W Teughels, ...
Journal of clinical periodontology 44 (1), 67-82, 2017
872017
LBA8_PR KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G De Castro Jr, ...
Annals of Oncology 29 (suppl_8), mdy424. 045, 2018
862018
Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
B Haaland, P San Tan, G de Castro Jr, G Lopes
Journal of Thoracic Oncology 9 (6), 805-811, 2014
852014
Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study
AG de Lima, RC Villar, G de Castro Jr, R Antequera, E Gil, ...
International Journal of Radiation Oncology* Biology* Physics 82 (1), 270-275, 2012
802012
High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous …
G de Castro, IML Snitcovsky, EMMS Gebrim, GM Leitão, W Nadalin, ...
European archives of oto-rhino-laryngology 264 (12), 1475, 2007
712007
The use of leucocyte and platelet‐rich fibrin in socket management and ridge preservation: a split‐mouth, randomized, controlled clinical trial
A Temmerman, J Vandessel, A Castro, R Jacobs, W Teughels, N Pinto, ...
Journal of clinical periodontology 43 (11), 990-999, 2016
702016
Osteonecrosis of the mandible associated with bevacizumab therapy
AR Santos-Silva, GAB Rosa, G de Castro Júnior, RB Dias, ACP Ribeiro, ...
Oral surgery, oral medicine, oral pathology and oral radiology 115 (6), e32-e36, 2013
652013
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20